Dusseldorf - Delayed Quote EUR
Jacobio Pharmaceuticals Group Co Ltd (77V.DU)
0.4360
+0.0240
+(5.83%)
At close: May 2 at 7:30:23 PM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
155,708
155,708
63,520
95,746
152,809
Cost of Revenue
--
--
60,317
83,112
139,979
Gross Profit
155,708
155,708
3,203
12,634
12,830
Operating Expense
358,904
358,904
411,431
486,344
315,154
Operating Income
-203,196
-203,196
-408,228
-473,710
-302,324
Net Non Operating Interest Income Expense
32,464
32,464
38,759
22,340
18,197
Pretax Income
-155,709
-155,709
-359,119
-371,861
-301,187
Net Income Common Stockholders
-155,709
-155,709
-359,119
-371,861
-301,187
Diluted NI Available to Com Stockholders
-155,709
-155,709
-359,119
-371,861
-301,187
Basic EPS
-0.46
-0.20
-0.46
-0.49
-0.40
Diluted EPS
-0.46
-0.20
-0.46
-0.49
-0.40
Basic Average Shares
776,281.5000
774,809
772,842
751,876
747,293
Diluted Average Shares
776,281.5000
774,809
772,842
751,876
747,293
Total Operating Income as Reported
-188,173
-188,173
-397,878
-394,201
-319,384
Total Expenses
358,904
358,904
471,748
569,456
455,133
Net Income from Continuing & Discontinued Operation
-155,709
-155,709
-359,119
-371,861
-301,187
Normalized Income
-159,487
-159,487
-348,781
-368,839
-310,655
Interest Income
40,863
40,863
47,071
24,610
18,765
Interest Expense
8,399
8,399
8,312
2,270
568
Net Interest Income
32,464
32,464
38,759
22,340
18,197
EBIT
-147,310
-147,310
-350,807
-369,591
-300,619
EBITDA
-120,852
-120,852
-325,727
-355,796
-289,828
Reconciled Cost of Revenue
--
--
60,317
83,112
139,979
Reconciled Depreciation
26,458
26,458
25,080
13,795
10,791
Net Income from Continuing Operation Net Minority Interest
-155,709
-155,709
-359,119
-371,861
-301,187
Total Unusual Items Excluding Goodwill
3,778
3,778
-10,338
-3,022
9,468
Total Unusual Items
3,778
3,778
-10,338
-3,022
9,468
Normalized EBITDA
-124,630
-124,630
-315,389
-352,774
-299,296
12/31/2021 - 1/9/2025
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade